Compare Nuwellis Inc (NUWE) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Oatly Group AB - ADR — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Oatly Group AB - ADR trades at $11.93 (market cap $330.93M). The key difference: Oatly Group AB - ADR is far larger — about 150.4× Nuwellis Inc's market cap, and Oatly Group AB - ADR is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Oatly Group AB - ADR for 18 Days on average.
| NUWE | OTLY | |
|---|---|---|
Market Cap | $2.20M | $330.93M |
Volume | 121,544 | 68,708 |
Sector | Health | Consumer Staples |
52-Week High | $146.65 | $15.91 |
52-Week Low | $0.68 | $8.03 |
Typical Hold Time | 26 Days | 18 Days |
Enterprise Value | -$1.52M | $835.34M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
OTLY trades at $10.37, down 1.33% today, with mixed technical signals showing bearish moving averages but bullish oscillators. The company reported Q2 2026 revenue growth and raised full-year guidance, though it continues to post significant net losses. Analyst sentiment is divided with a $12.28 consensus price target representing 18% upside potential. Cash flow remains negative but improving, with operating losses narrowing from -$269M in 2022 to -$24M in 2025.
The investment case hinges on OTLY's revenue growth acceleration and path to profitability, but high debt levels and persistent losses present substantial risk. While the stock offers potential upside to analyst targets, investors must weigh the company's improving operational trends against its negative equity and cash burn. The upcoming Q3 2026 earnings report on October 28 will be critical for validating management's turnaround narrative.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
